Navigation Links
Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
Date:4/19/2011

SAN DIEGO, April 19, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that AM152, the company's lead LPA1 antagonist, has been granted an orphan drug designation by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis. Commonly referred to as IPF, this fibrotic disease affects the lungs of patients and their ability to breathe.

"This is an important development for Amira, and potentially patients suffering from IPF, as we continue to move this promising therapeutic candidate forward in development," said Bob Baltera, Chief Executive Officer.  "We are currently completing our Phase 1 studies with AM152 and expect to begin a Phase 2 study by the end of 2011 or in early 2012.  Currently there are no FDA-approved therapies for IPF, and we look forward to better understanding the potential therapeutic benefit of an LPA1 antagonist in this disease area."

AM152 is a lysophosphatidic acid (LPA) receptor 1 antagonist.  Activation of the LPA1 receptor by LPA has been implicated in a number of disease processes, including tissue fibrosis.  LPA1 receptor antagonists have displayed efficacy in a wide range of preclinical fibrosis models, including lung, skin, eye, liver and kidney.

About Orphan Drug Designation

The United States Orphan Drug Act of 1983 was created to promote and support the development of new drug therapies for diseases that affect fewer than 200,000 people in the United States.  Orphan Drug Designation provides a sponsor seven years of market exclusivity for the designated therapeutic indication in the United States, from the point at which the therapy is granted marketing approval.  Orphan Drug Designation also provides access to regulatory support from the FDA, potential FDA fee reductions and tax credits related to development expenses.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals i
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
2. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
3. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
4. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
5. Visage Imaging Releases Amira 5.3
6. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
7. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
8. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
9. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
10. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
11. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that ... in its catalogue: Wireless Opportunities ... Zigbee, UWB WWAN, WMAN, WLAN and other ... Kalorama Information,s Wireless Opportunities in ... UWB WWAN, WMAN, WLAN and other technologies) ...
(Date:8/20/2014)... , Aug. 20, 2014   Ventana ... Roche  Group, today announced that its VENTANA System ... marked in the European Union for routine pathology, ... system, consisting of VENTANA Virtuoso software coupled with ... iScan HT slide scanner, provides automated digital slide ...
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
Breaking Medicine Technology:Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 2Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 3Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 4Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 5Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 6Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 7Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 8Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 9Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 10Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 11Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 12Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 13Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 14Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 15Wireless Opportunities in Healthcare (The Market for Bluetooth, RFID, Zigbee, UWB WWAN, WMAN, WLAN and other technologies) 16Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3
... Dec. 8 Halozyme Therapeutics, Inc.,(Nasdaq: HALO ... extracellular matrix, today announced that Roche has,dosed the first ... a,subcutaneous formulation using Enhanze Technology of a biologic directed ... payment under the,agreement. , ...
... Positive Opinion for TEMODAL(R) Intravenous Formulation and Oral TEMODAL ... EU Patients with Certain Primary Brain Tumors , ... Schering-Plough Corporation (NYSE: SGP ) today ... Use (CHMP) of the European Medicines Agency (EMEA) has ...
Cached Medicine Technology:Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 2Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 3Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target 4CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 2CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 3CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 4CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 5CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors 6
(Date:8/20/2014)... 2014 IQ Formulations , a top ... the Inc. 500 , distinguishing it as one of ... Formulations not only made the list, but was ranked in ... the past three years. It also ranked ninth among all ... and the second fastest growing company in the Miami metro ...
(Date:8/20/2014)... It’s no secret that millions of ... National Institute on Drug Abuse, nearly 24 million Americans ... more alarming is the fact that the total number ... Those locked in a struggle with substance abuse often ... now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... 2014 A Missouri federal judge has remanded ... were treated with GranuFlo and NaturaLyte to the City of ... Baron and Budd. The judge rejected an assertion by the ... were invalid. (McGee, et al. v. Fresenius Medical Care North ... Medical Care, is the manufacturer of the dialysis products GranuFlo ...
(Date:8/20/2014)... 2014 Botanica Day Spa ... Utilizing the new and popular stem cell line ... lines and wrinkles and naturally repairs the skin. ... the new service by offering clients a complimentary ... cell facial. , Pevonia® continues to be a ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3
... say , WEDNESDAY, Nov. 21 (HealthDay News) -- ... certain sounds, such as the sound of a familiar voice ... Washington, Seattle, and the University of California, Los Angeles, ... activity associated with a given sound task can also identify ...
... vascular disease is widespread and often deadly among older ... treat it, according to a new report by a ... Center and Weill Cornell Medical College campuses of NewYork-Presbyterian ... fact that for years, cardiovascular research has focused almost ...
... Revenues Increase 89% to $3.51 Million versus $1.85 ... Million for Q3 of 2006, -- Third ... ... /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,International, Inc. (OTC Bulletin Board: CYXI), a leading provider in ...
... Eclipsys Corporation(R),(Nasdaq: ECLP ), The Outcomes ... Merrill Lynch Health Services Investor Conference,taking place next ... http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO ), Eclipsys executives will present ... a.m. Eastern time. Interested parties are invited to,listen ...
... 21 Shamir,Optical Industry Ltd. (Nasdaq: SHMR ) ... on Tuesday, November 27, 2007, and has,scheduled a conference ... that,morning., The conference call will be broadcast live ... http://www.kcsa.com approximately five minutes before,the conference call ...
... best value for money, study finds , WEDNESDAY, Nov. 21 ... and programs to improve the quality and value of their ... 21 issue of the Journal of the American Medical ... 609 executives of the largest employers in 41 U.S. ...
Cached Medicine News:Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 2Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 3Health News:Arterial vascular disease underdiagnosed, undertreated in older US women 4Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 2Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 3Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 4Health News:China Yingxia International Announces 2007 Third Quarter Financial Results Conference Call 5Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 2Health News:Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 3Health News:Shamir Optical Industry Ltd. to Host Conference Call Announcing Third Quarter 2007 Earnings Results 2Health News:Most U.S. Companies Do Little to Boost Worker Health Benefits 2
... Calvin Klein Collection. Provocatively inspired for ... a bold outlook. Innovative structure: soft-sculpted ... technology enhances modern design. Technological sophistication ... enhance the face., ,The Calvin Klein ...
... Marc Jacobs is ... very first collection in ... unveiling a range of ... that are defined by ...
... new GUCCI DONNA eyewear collection celebrates the ... a vintage yet contemporary feel, the unmistakable ... new GUCCI UOMO optical and sunglass collection, ... classic lines with cutting-edge design that is ...
The Alexander McQueen eyewear collection focuses on a distinctive sophisticated style, with feminine lines, assertive shapes and original silhouettes....
Medicine Products: